NCT03885947View on ClinicalTrials.gov

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 21, 2019

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Hematological MalignancyAcute Leukemia in RemissionAcute Lymphoblastic Leukemia in RemissionMyelodysplastic SyndromesNon-Hodgkin LymphomaHodgkin Lymphoma
Interventions
BIOLOGICAL

Cord blood stem cells

CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .

DRUG

Valproic Acid

Valproic Acid (VPA) expanded cord blood stem cells

DRUG

Fludarabine

Fludarabine 150 mg/m2

DRUG

cytoxan

Cytoxan 50 mg/m2

DRUG

Thiotepa

Thiotepa 10 mg/m2

BIOLOGICAL

TBI

TBI 400cGy

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Alla Keyzner

OTHER

NCT03885947 - VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | Biotech Hunter | Biotech Hunter